Mode of Action of the Monobactam LYS228 and Mechanisms Decreasing In Vitro Susceptibility in Escherichia coli and Klebsiella pneumoniae
Author(s) -
Charles R. Dean,
David T. Barkan,
Alun Bermingham,
Johanne Blais,
Fergal Casey,
Anthony Casarez,
Richard A. Colvin,
John Fuller,
Adriana K. Jones,
Cindy Li,
Sara López,
Louis E. Metzger,
Mina Mostafavi,
Ramadevi Prathapam,
Dita Rasper,
Folkert Reck,
Alexey Ruzin,
Jacob Shaul,
Xiaoyu Shen,
Robert L. Simmons,
Peter Skewes-Cox,
Kenneth T. Takeoka,
Pramila Tamrakar,
Tsuyoshi Uehara,
Jun-Rong Wei
Publication year - 2018
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01200-18
Subject(s) - klebsiella pneumoniae , escherichia coli , microbiology and biotechnology , mode of action , in vitro , enterobacteriaceae , klebsiella , biology , escherichia , genetics , gene , toxicology
The monobactam scaffold is attractive for the development of new agents to treat infections caused by drug-resistant Gram-negative bacteria because it is stable to metallo-β-lactamases (MBLs). However, the clinically used monobactam aztreonam lacks stability to serine β-lactamases (SBLs) that are often coexpressed with MBLs.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom